Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 2 Interventional

ASTAR: Sacituzumab Govitecan For Breast Cancer

ClinicalTrials.gov ID: NCT07947823

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07947823. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 10:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Adjuvant Sacituzumab Govitecan (SG) in High-risk Early-stage HR+/HER2- Breast Cancer (ASTAR)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are: * Is sacituzumab govitecan safe for individuals with this type of cancer? * Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.

Study identification

NCT ID
NCT07947823
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
32 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 21, 2027 (Estimated)
Primary completion
Sep 1, 2028 (Estimated)
Completion
Sep 1, 2030 (Estimated)
Last update posted
Nov 19, 2026

2027 – 2030

United States locations

U.S. sites
5
U.S. states
1
U.S. cities
4
Facility City State ZIP Site status
Massachusetts General Hospital Boston Massachusetts 02114 —
Brigham & Women's Hospital Boston Massachusetts 02115 —
Mass General Cancer Center in Danvers Danvers Massachusetts 01923 —
Mass General Cancer Center at Newton-Wellesley Hospital Newton Massachusetts 02462 —
Mass General Waltham Waltham Massachusetts 02451 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07947823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2026 · Synced Nov 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.